Modulating Movement Intention Via Cortical Stimulation

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Inclusion Criteria: (Healthy Controls) * Fluent in English (Patients with PMD or PNES): * Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders. * Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening Exclusion Criteria: * Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI * Chronic or progressive medical condition * Any history of traumatic brain injury or significant head trauma * Currently meets criteria for substance abuse or dependence * History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation * Pregnancy * Metal or devices in the head, including neurostimulators or metal foreign bodies * Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS. * Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.). * Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009 * Current diagnosis of any inflammatory or autoimmune disorder within last 6 months PMD and PNES Patients * Any history of traumatic brain injury or significant head trauma * Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures; * Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s); * Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months * Metal or devices in the head, including neurostimulators or metal foreign bodies * Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009; * Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24; * Recurrent visual hallucinations, within the past 6 months; * History of significant uncontrollable movements of the head; * Any clinically significant abnormality on vital signs